A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

A price-sensitive, value-conscious consumer adds a degree of unevenness and uncertainty to a robust earnings season.

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

CEO Alex Karp used the company's earnings call to dismiss his critics, saying, "Enjoy, get some popcorn, they're crying." ...

Asian shares have retreated despite the big lift in overseas markets from optimism over AI technology. Shares declined ...

Kimberly-Clark has demonstrated its ambitions in the consumer healthcare segment after agreeing to buy Neutrogena, Tylenol ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...